Return to content in this issue

Omalizumab in the Treatment of Hyper-IgE Syndrome: 2 Case Reports

Gomes N^1*, Miranda J^2*, Lopes S¹, Carneiro-Leão L², Torres Costa J², Baudrier T¹, Azevedo F<sup>1

1</sup>Dermatovenereology Department, Centro Hospitalar Universitário de São João, Porto, Portugal
²Allergy and Clinical Immunology Department, Centro Hospitalar Universitário de São João, Porto, Portugal
^*These authors are to be considered first authors.

J Investig Allergol Clin Immunol 2020; Vol 30(3) : 191-192
doi: 10.18176/jiaci.0469

• Abstract
• Supplemental Materials

Key words: DOCK8, Eczema, Hyper-IgE syndrome, Omalizumab, STAT3

	Title	Type	Size
	doi10.18176_jiaci.0469_supplemental-materials_2.pdf	pdf	581.03 Kb